{"id":365995,"date":"2016-12-19T06:06:03","date_gmt":"2016-12-19T06:06:03","guid":{"rendered":"https:\/\/www.pm360online.com\/?guid=5d766e46ec316c78de551498797eb178"},"modified":"2016-12-19T06:06:03","modified_gmt":"2016-12-19T06:06:03","slug":"mdxhealth-announces-acecgt-life-science-limited-as-the-exclusive-distributor-for-selectmdx-in-hong-kong-and-macao-china","status":"publish","type":"post","link":"https:\/\/www.pm360online.com\/mdxhealth-announces-acecgt-life-science-limited-as-the-exclusive-distributor-for-selectmdx-in-hong-kong-and-macao-china\/","title":{"rendered":"MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China"},"content":{"rendered":"

PRESS RELEASE \/ REGULATED INFORMATION \u00a0\/\u00a0INSIDE INFORMATION
\u00a0\u00a0<\/b>
IRVINE, CA, and HERSTAL, BELGIUM<\/b> – December 19, 2016 – MDxHealth<\/a> SA (Euronext: MDXH.BR) announced today that it has signed a distribution agreement with AceCGT Life Science Limited for their SelectMDx(TM) for Prostate Cancer assay in Hong Kong and Macao, Special Administrative Regions of the People’s Republic of China.<\/p>\n

Under the terms of the agreement, AceCGT Group will be the exclusive distributor within the Hong Kong and Macao Special Administrative Regions. Patient samples will be sent to MDxHealth’s state-of-the-art ISO certified clinical diagnostic laboratory in Nijmegen, The Netherlands for analysis. <\/p>\n

“We are delighted to announce our collaboration with AceCGT Group for the distribution of SelectMDx within the People’s Republic of China. We believe that SelectMDx perfectly complements AceCGT Group’s cutting edge molecular diagnostic test menu,” commented<\/b> Dr. Jan Groen, CEO of MDxHealth. <\/b>“With their highly qualified and experienced team of laboratory scientists, clinical researchers and a dedicated commercial team, AceCGT Group is an ideal partner to help us raise awareness and expand access to SelectMDx throughout Hong Kong and Macao.”<\/p>\n

About SelectMDx for Prostate Cancer<\/a><\/p>\n

SelectMDx for Prostate Cancer is a proprietary urine-based, molecular diagnostic test that offers a non-invasive ‘liquid biopsy’ method to assess a man’s risk for prostate cancer. SelectMDx helps identify men at increased risk of harbouring aggressive, potentially lethal, prostate cancer who may benefit most from a prostate biopsy and earlier detection. The test delivers a negative predictive value (NPV) of 98% for clinically significant disease, helping to reduce unnecessary MRI procedures and invasive prostate biopsies by approximately 50%, thereby reducing healthcare costs.<\/p>\n

About AceCGT Group <\/a><\/p>\n

AceCGT is a Hong Kong based leading clinical diagnostic laboratory committed in bringing innovative, affordable and widely accessible testing solutions into everyday clinical practice within multiple specialties throughout their network. \u00a0Leveraging the vast amount of knowledge and know-how derived from the Human Genome Project, International HapMap and other oncology research programs, AceCGT is translating the science of molecular diagnostics and personalized medicine into clinical practice within the Hong Kong and Macao Special Administrative Regions of China.\u00a0 For more information, visit www.acecgtdiagnostic.com<\/a>.<\/p>\n

About MDxHealth<\/a><\/p>\n

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company’s European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com<\/a> and follow us on Twitter at: twitter.com\/mdxhealth<\/a>. <\/p>\n\n\n
For more information: <\/b><\/p>\n

\u00a0<\/b><\/p>\n

Dr. Jan Groen, CEO
MDxHealth
US: +1 949 812 6979
BE: +32 4 364 20 70
info@mdxhealth.com<\/a>\u00a0 <\/td>\n

 \u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0 <\/td>\n

 \u00a0<\/p>\n

\u00a0<\/p>\n

Jonathan Birt, Chris Welsh, Hendrik Thys (PR & IR)
Consilium Strategic Communications
UK: +44 20 3709 5701
US: +1 917 322 2571 (Rx Communications Group LLC)
mdxhealth@consilium-comms.com<\/a><\/p>\n

\u00a0 <\/td>\n<\/tr>\n<\/table>\n

<\/p>\n\n\n
\u00a0<\/td>\n<\/tr>\n<\/table>\n

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.\u00a0 This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.<\/i><\/p>\n

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.<\/i><\/p>\n

Attachments: <\/p>\n

http:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/55626d23-2dcc-414c-b66b-baf5c38764af<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

PRESS RELEASE \/ REGULATED INFORMATION  \/ INSIDE INFORMATION
  <\/b>
IRVINE, CA, and HERSTAL, BELGIUM<\/b> – December 19, 2016 – MDxHealth<\/a> SA (Euronext: MDXH.BR) announced today that it has signed a distribution agreement with AceCGT Life Science Limited for their SelectMDx(TM) for Prostate Cancer assay in Hong Kong and Macao, Special Administrative Regions of the People’s Republic of China.<\/p>\n

Under the terms of the agreement, AceCGT Group will be the exclusive distributor within the Hong Kong and Macao Special Administrative Regions. Patient samples will be sent to MDxHealth’s state-of-the-art ISO certified clinical diagnostic laboratory in Nijmegen, The Netherlands for analysis. <\/p>\n

“We are delighted to announce our collaboration with AceCGT Group for the distribution of SelectMDx within the People’s Republic of China. We believe that SelectMDx perfectly complements AceCGT Group’s cutting edge molecular diagnostic test menu,” commented<\/b> Dr. Jan Groen, CEO of MDxHealth. <\/b>“With their highly qualified and experienced team of laboratory scientists, clinical researchers and a dedicated commercial team, AceCGT Group is an ideal partner to help us raise awareness and expand access to SelectMDx throughout Hong Kong and Macao.”<\/p>\n

About SelectMDx for Prostate Cancer<\/a><\/p>\n

SelectMDx for Prostate Cancer is a proprietary urine-based, molecular diagnostic test that offers a non-invasive ‘liquid biopsy’ method to assess a man’s risk for prostate cancer. SelectMDx helps identify men at increased risk of harbouring aggressive, potentially lethal, prostate cancer who may benefit most from a prostate biopsy and earlier detection. The test delivers a negative predictive value (NPV) of 98% for clinically significant disease, helping to reduce unnecessary MRI procedures and invasive prostate biopsies by approximately 50%, thereby reducing healthcare costs.<\/p>\n

About AceCGT Group <\/a><\/p>\n

AceCGT is a Hong Kong based leading clinical diagnostic laboratory committed in bringing innovative, affordable and widely accessible testing solutions into everyday clinical practice within multiple specialties throughout their network.  Leveraging the vast amount of knowledge and know-how derived from the Human Genome Project, International HapMap and other oncology research programs, AceCGT is translating the science of molecular diagnostics and personalized medicine into clinical practice within the Hong Kong and Macao Special Administrative Regions of China.  For more information, visit www.acecgtdiagnostic.com<\/a>.<\/p>\n

About MDxHealth<\/a><\/p>\n

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company’s European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com<\/a> and follow us on Twitter at: twitter.com\/mdxhealth<\/a>. <\/p>\n\n\n
For more information: <\/b><\/p>\n

 <\/b><\/p>\n

Dr. Jan Groen, CEO
MDxHealth
US: +1 949 812 6979
BE: +32 4 364 20 70
info@mdxhealth.com<\/a>  <\/td>\n

  <\/p>\n

 <\/p>\n

  <\/td>\n

  <\/p>\n

 <\/p>\n

Jonathan Birt, Chris Welsh, Hendrik Thys (PR & IR)
Consilium Strategic Communications
UK: +44 20 3709 5701
US: +1 917 322 2571 (Rx Communications Group LLC)
mdxhealth@consilium-comms.com<\/a><\/p>\n

  <\/td>\n<\/tr>\n<\/table>\n

<\/p>\n\n\n
 <\/td>\n<\/tr>\n<\/table>\n

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.  This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.<\/i><\/p>\n

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.<\/i><\/p>\n

Attachments: <\/p>\n

http:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/55626d23-2dcc-414c-b66b-baf5c38764af<\/a><\/p>\n","protected":false},"author":74553,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[71350,71360],"tags":[],"_links":{"self":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/365995"}],"collection":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/users\/74553"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/comments?post=365995"}],"version-history":[{"count":0,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/365995\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/media?parent=365995"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/categories?post=365995"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/tags?post=365995"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}